Filing Details
- Accession Number:
- 0001140361-13-035373
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-09-09 13:06:40
- Reporting Period:
- 2013-09-05
- Filing Date:
- 2013-09-09
- Accepted Time:
- 2013-09-09 13:06:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1377232 | Phd J Michael Williams | One Idexx Drive Westbrook ME 04092 | Executive Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-09-05 | 4,149 | $34.37 | 14,916 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-09-05 | 5,162 | $95.58 | 9,754 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-09-05 | 4,149 | $0.00 | 4,149 | $34.37 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,241 | 2016-02-13 | No | 4 | M | Direct |
Footnotes
- Includes 68 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 06/28/2013.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $95.3708 to $95.65, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock becomes exercisable as to 4,149 shares on 02/14/2010 and 02/14/2013, 4,150 shares on 02/14/2011 and 02/14/2012 and the remaining 1,241 shares on 02/14/2014.